Clinical oncologist, Gynecologic oncologist
Head of the Gynaecological Tumour Unit at Medical Oncology Department at the Vall d’Hebron University Hospital; Principal Clinical Investigator of the Gynaecological Malignancies Group at the Vall d’Hebrón Institute of Oncology in Barcelona; Leader of the Gynaecological Cancer programme at the Institute of Oncology
Dr. Ana Oaknin is a Medical Oncologist with expertise in angiogenesis, DNA repair, and immunology. She focuses on gynecological cancers. Dr. Oaknin earned her medical degree and MD in Medical Oncology from Complutense University of Madrid. She also holds a PhD from Universidad Autonoma de Barcelona.
Dr. Oaknin is Co-Chair of the GEICO Group. She is a faculty member for the Gyn-Track in the European Society of Medical Oncology. She represents Spain in the GOG and GCIG committees. Dr. Oaknin is an active member of ASCO, ESMO, and SEOM. She has published over 100 scientific articles and presentations. She also leads several clinical trials in ovarian, cervical, and endometrial cancer.
Her main research interests are in angiogenesis, DNA repair mechanisms and immunology, and is Principal Investigator in several series of clinical trials in ovarian, cervical and endometrial cancer.
She is leading and involved in a large number of projects on gynaecological tumours. She is the author of over 100 publications and presentations in different Congress.
Formation
Who knows more about the doctor, amenities, and hospital staff than someone who has checked everything themselves? We collect the genuine experiences of our patients for you to make the best choice.
Each review belongs to a verified customer after getting medical services booked via Bookimed.com.
We publish positive and negative reviews, moderated for compliance with Reviews & Comments Policy.
I really liked the specialist himself, a very good-natured man without pathos, n
The easiest way of finding you best doctor
The format is quite simple, everything is accessible and understandable, the doctor is very qualified. I will not say that we talked about clinical studies, there was no definitive information. We are... Read more